Wilmington Eye Now Offering iDose(R) TR as a New Treatment Option to Reduce Eye Pressure in Patients With Ocular Hypertension and Open-Angle Glaucoma [Yahoo! Finance]
Glaukos Corporation (GKOS)
Last glaukos corporation earnings: 2/27 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.glaukos.com/investors/investor-overview/default.aspx
Company Research
Source: Yahoo! Finance
WILMINGTON, NC / ACCESSWIRE / May 28, 2024 / Wilmington Eye is proud to announce the availability of iDose® TR (travoprost intraocular implant) 75 mcg. iDose TR is a new, FDA approved treatment that is designed to provide long duration, continuous drug therapy directly inside the eye, helping patients take better control over the elevated eye pressure associated with open-angle glaucoma or ocular hypertension. Glaucoma is an eye disease caused by increased eye pressure and can also damage the optic nerve, which carries visual information from the eyes to the brain. If left untreated, glaucoma can cause permanent damage to the eye, which means vision loss cannot be reversed. Prescription eye drops are the most common treatment for glaucoma, but they can be difficult to administer correctly and can cause uncomfortable or irritating side effects for most patients. High rates of non-compliance and non-adherence to prescription medications contribute to disease progression. "With iDos
Show less
Read more
Impact Snapshot
Event Time:
GKOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GKOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GKOS alerts
High impacting Glaukos Corporation news events
Weekly update
A roundup of the hottest topics
GKOS
News
- Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock [Yahoo! Finance]Yahoo! Finance
- Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common StockBusiness Wire
- Glaukos (GKOS) Gains 40.4% YTD: What's Driving the Rally? [Yahoo! Finance]Yahoo! Finance
- Glaukos Co. (NYSE: GKOS) had its price target raised by analysts at Stifel Nicolaus from $110.00 to $130.00. They now have a "buy" rating on the stock.MarketBeat
- Glaukos Co. (NYSE: GKOS) had its price target raised by analysts at Wells Fargo & Company from $110.00 to $120.00. They now have an "overweight" rating on the stock.MarketBeat
GKOS
Earnings
- 5/1/24 - Miss
GKOS
Sec Filings
- 6/14/24 - Form 8-K
- 6/5/24 - Form 4
- 6/5/24 - Form 8-K
- GKOS's page on the SEC website